For example, work from our group has indicated that higher-baseline CSF VEGFA levels are associated with slower rates of hippocampal atrophy and slower rates of cognitive decline [3], particularly among individuals with elevated levels of AD biomarkers. The gene discussed is VEGFA; the disease is Alzheimer disease.